Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods

International Journal of Pharmaceutics

Volumn 272, Issue 1-2, 2004, Pages 1-10

  Sethia, S ^a   Squillante, E ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Amorphous; Carbamazepine; PVP K30; Solid dispersions; Supercritical fluid; TPGS

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; AMPHOPHILE; CARBAMAZEPINE; DEXTRO ALPHA TOCOPHERYL GLYCOL 1000 SUCCINATE; DRUG CARRIER; GELUCIRE; GELUCIRE 14; GELUCIRE 44; LIPID; POVIDONE; POVIDONE K25; POVIDONE K30; SOLVENT; UNCLASSIFIED DRUG;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; EVAPORATION; INFRARED SPECTROSCOPY; MELTING POINT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUPERCRITICAL FLUID CHROMATOGRAPHY; THERMOGRAPHY; X RAY POWDER DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; POLYETHYLENE GLYCOLS; POVIDONE; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; VITAMIN E; X-RAY DIFFRACTION;

EID: 1442348833     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.11.025     Document Type: Article

References (26)

1. Beach S., Latham D., Sidgwick C., Hanna M., York P. Control of the physical form of salmeterol xinafoate. Org. Process Res. Dev. 3:1999;370-376.
2. Behme R.J., Brooke D. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J. Pharm. Sci. 80:1991;986-990.
3. Bertillson L. Clinical pharmacokinetics of carbamazepine. Clin. Pharmacokinet. 3:1978;128-143.
4. Ford J.L. The current status of solid dispersions. Pharm. Acta Helv. 61:1986;69-88.
5. Gallagher P.M., Coffey M.P., Krukonis V.J., Klasutis N. Gas antisolvent recrystallization: a new process to recrystallize compounds in supercritical fluids. Am Chem. Soc. Symp. Ser. 406:1989;334-354.
6. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4:1965;117-210.
7. Kaplan S.A. Biopharmaceutical considerations in drug formation design and evaluation. Drug Metab. Rev. 1:1972;15-34.
8. Khoo S.M., Porter C.J.H., Charman W.N. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int. J. Pharm. 205:2000;65-78.
9. Krahn F.U., Mielck J.B. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm. Acta Helv. 67:1987;247-254.
10. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50:2000;47-60.
11. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50:2000;3-12.
12. Lowes M.M.J., Caira M.R., Lotter A.P., Van Der Watt J.G. Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. J. Pharm. Sci. 76:1987;744-752.
13. Matsumoto T., Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm. Res. 16:1999;1722-1728.
14. Mayersohn M., Gibaldi M. New method of solid-state dispersion for increasing dissolution rates. J. Pharm. Sci. 55:1966;1323-1324.
15. Moneghini M., Kikic I., Voinovich D., Perissutti B., Filipovic-Grcic J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int. J. Pharm. 222:2001;129-138.
16. Nair R., Nyamweya N., Gönen S., Martínez-Miranda L.J., Hoag S.W. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation. Int. J. Pharm. 225:2001;83-96.
17. Nogami H., Nagai T., Suzuki A. Studies on powdered preparations. XVII. Dissolution rate of sulfonamides by rotating disk method. Chem. Pharm. Bull. 14:1966;329-338.
18. Rustichelli C., Gamberini G., Ferioli V., Gamberini M.C., Ficarra R., Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biomed. Anal. 23:2000;41-54.
19. Serajuddin A.T.M. Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88:1999;1058-1066.
20. Sethia S., Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J. Pharm. Sci. 91:2002;1948-1957.
21. Sethia S., Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 20:2003;215-247.
22. Silverstein, R.M., Bassler, G.C., Morril, T.C., 1991. Spectrometric Identification of Organic Compounds. Wiley, New York, pp. 91-131.
23. Taylor L.S., Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14:1997;1691-1698.
24. Van den Mooter G., Augustijns P., Blaton N., Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int. J. Pharm. 164:1998;67-80.
25. Van den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 12:2001;261-269.
26. York P. Strategies for particle design using supercritical fluid technologies. Pharm. Sci. Tech. Today. 2:1999;430-440.